How do you pay?

How to pay the least

Ask for the cash price

Empaveli

We didn’t find one.

  1. Ask your pharmacy for Empaveli’s cash price, and one or two other pharmacies too.
  2. Empaveli’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameEmpaveli
Authorized genericpegcetacoplan
Regular genericpegcetacoplan
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Empaveli?
The original
–
–

Brand nameThe maker’s card

Apellis Copay Program (ApellisAssist)

Savings card from Apellis Pharmaceuticals

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Sign up on empaveli.com 

Or call 1-866-692-7527.

In the maker’s words

“You may pay as little as $0 for EMPAVELI with our Copay Program…”

From the maker’s offer on empaveli.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Empaveli itself, from the same company, sold without the brand name, and usually for less. For now Empaveli is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

EMPAVELI is a complement inhibitor indicated:

  • for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
  • for the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce proteinuria and the loss of kidney function.

Source: the FDA label for Empaveli (Apellis Pharmaceuticals, Inc.), August 21, 2026. Full label on DailyMed 

Good to know